Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Holdings Lifted by Manning & Napier Advisors LLC

Manning & Napier Advisors LLC lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 37.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 267,602 shares of the medical research company's stock after purchasing an additional 73,575 shares during the quarter. Thermo Fisher Scientific comprises 1.6% of Manning & Napier Advisors LLC's holdings, making the stock its 19th largest position. Manning & Napier Advisors LLC owned approximately 0.07% of Thermo Fisher Scientific worth $139,215,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of TMO. VanderPol Investments L.L.C. increased its position in shares of Thermo Fisher Scientific by 7.7% in the fourth quarter. VanderPol Investments L.L.C. now owns 390 shares of the medical research company's stock valued at $203,000 after buying an additional 28 shares in the last quarter. Invesco LLC raised its holdings in shares of Thermo Fisher Scientific by 1.9% during the fourth quarter. Invesco LLC now owns 10,870 shares of the medical research company's stock valued at $5,655,000 after acquiring an additional 204 shares during the last quarter. Swedbank AB boosted its stake in shares of Thermo Fisher Scientific by 19.1% in the fourth quarter. Swedbank AB now owns 1,423,155 shares of the medical research company's stock worth $740,368,000 after acquiring an additional 228,475 shares during the last quarter. Strategic Blueprint LLC lifted its holdings in Thermo Fisher Scientific by 7.2% in the 4th quarter. Strategic Blueprint LLC now owns 1,368 shares of the medical research company's stock valued at $712,000 after purchasing an additional 92 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. lifted its stake in shares of Thermo Fisher Scientific by 5.4% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 605,113 shares of the medical research company's stock worth $314,798,000 after buying an additional 30,758 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

TMO has been the topic of several analyst reports. Robert W. Baird reduced their price target on Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating on the stock in a report on Thursday, October 24th. Bank of America lowered their price objective on Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating for the company in a research report on Friday, December 13th. TD Cowen upped their price target on Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. StockNews.com raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, January 14th. Finally, Evercore ISI dropped their price target on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an "outperform" rating for the company in a research report on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $648.95.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded up $38.83 during midday trading on Thursday, hitting $607.06. 3,349,652 shares of the stock were exchanged, compared to its average volume of 2,113,224. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The company has a 50 day moving average price of $537.83 and a 200-day moving average price of $570.33. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The stock has a market cap of $232.20 billion, a P/E ratio of 38.06, a PEG ratio of 3.82 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.26%. The ex-dividend date of this dividend was Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio is presently 9.78%.

Thermo Fisher Scientific announced that its Board of Directors has initiated a share repurchase program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's management believes its shares are undervalued.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the transaction, the chief executive officer now directly owns 111,192 shares of the company's stock, valued at $58,960,669.92. This represents a 8.25 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Over the last quarter, insiders sold 34,850 shares of company stock worth $19,123,197. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.